Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2075105 | 0.91 | SLC6A2 (0.44) | SLC6A2SLC6A4HDAC8HTR2AHRH1 | |
| SCHEMBL2074789 | 0.83 | HDAC8 (0.48) | SLC6A2SLC6A4HDAC8GCGRHTR2A | |
| SCHEMBL2072547 | 0.82 | SLC6A2 (0.59) | SLC6A2SLC6A4HTR2AHRH1SLC6A3 | |
| SCHEMBL12933717 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4HDAC8GCGRHTR2A | |
| SCHEMBL2073811 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4GCGRHTR2AHRH1 | |
| SCHEMBL2073824 | 0.80 | SLC6A2 (0.67) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL2071320 | 0.76 | SLC6A2 (0.44) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL2071162 | 0.76 | KMO (0.49) | SLC6A2SLC6A4HTR2AHRH1SLC6A3 | |
| SCHEMBL12933718 | 0.76 | SLC6A2 (0.44) | SLC6A2SLC6A4HTR2AHRH1SLC6A3 | |
| SCHEMBL2074283 | 0.76 | SLC6A2 (0.41) | SLC6A2SLC6A4HTR2AHRH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | SLC6A2 9/4885SLC6A4 14/4885HDAC8 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.